Skip to main content

SRA737 + anti–PD-L1 therapy and low-dose gemcitabine shows early promise for SCLC

Primary tabs

View
Get Stamp Tags
Published Locations

Breadcrumb

Home
SRA737 + anti–PD-L1 therapy and low-dose gemcitabine shows early promise for SCLC

User login

Username

Password

Reset your password

Type	Lead	score